Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Barclays Analyst Says

by · The Markets Daily

Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price objective upped by research analysts at Barclays from $84.00 to $95.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage presently has an “equal weight” rating on the biopharmaceutical company’s stock. Barclays‘s target price suggests a potential downside of 1.71% from the company’s previous close.

Other equities analysts have also issued research reports about the company. BMO Capital Markets raised their price target on Gilead Sciences from $85.00 to $94.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Wells Fargo & Company upped their price target on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday. Cantor Fitzgerald lifted their price objective on Gilead Sciences from $70.00 to $80.00 and gave the stock a “neutral” rating in a report on Thursday. Royal Bank of Canada reiterated a “sector perform” rating and issued a $75.00 price target on shares of Gilead Sciences in a research report on Tuesday, October 29th. Finally, JPMorgan Chase & Co. lifted their price objective on Gilead Sciences from $95.00 to $100.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 9th. Ten investment analysts have rated the stock with a hold rating, eleven have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and an average target price of $88.65.

Get Our Latest Stock Analysis on Gilead Sciences

Gilead Sciences Stock Up 5.4 %

Shares of NASDAQ:GILD traded up $4.96 on Thursday, hitting $96.65. 2,920,497 shares of the company’s stock were exchanged, compared to its average volume of 6,993,893. The firm’s 50-day moving average is $84.58 and its 200 day moving average is $74.67. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.95 and a current ratio of 1.14. The company has a market capitalization of $120.33 billion, a PE ratio of 117.88, a P/E/G ratio of 3.13 and a beta of 0.17. Gilead Sciences has a 1-year low of $62.07 and a 1-year high of $98.32.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. Gilead Sciences’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.29 earnings per share. Sell-side analysts predict that Gilead Sciences will post 3.75 EPS for the current year.

Insiders Place Their Bets

In related news, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the sale, the insider now directly owns 78,127 shares in the company, valued at approximately $6,545,480.06. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the sale, the insider now directly owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the transaction, the insider now directly owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 36,847 shares of company stock worth $3,033,340 over the last quarter. 0.29% of the stock is owned by corporate insiders.

Institutional Trading of Gilead Sciences

A number of hedge funds have recently made changes to their positions in the stock. GSA Capital Partners LLP bought a new stake in shares of Gilead Sciences in the 1st quarter worth about $462,000. Envestnet Portfolio Solutions Inc. increased its holdings in Gilead Sciences by 31.8% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 112,743 shares of the biopharmaceutical company’s stock valued at $8,258,000 after buying an additional 27,211 shares during the last quarter. Quantbot Technologies LP acquired a new stake in Gilead Sciences during the first quarter valued at approximately $573,000. AIA Group Ltd bought a new position in Gilead Sciences during the 1st quarter worth approximately $1,684,000. Finally, SG Americas Securities LLC grew its position in shares of Gilead Sciences by 51.2% in the 1st quarter. SG Americas Securities LLC now owns 154,992 shares of the biopharmaceutical company’s stock worth $11,353,000 after acquiring an additional 52,494 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

About Gilead Sciences

(Get Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

See Also